Feng Zhang unveils a new technology to potentially deliver mRNA, gene therapy, CRISPR and more
MIT star researcher and CRISPR pioneer Feng Zhang put a new paper out Thursday in Science detailing how a new technology could alter a field that’s already proven game-changing throughout the Covid-19 pandemic.
Zhang and his team have developed a potential new delivery method for mRNA therapeutics, they reported in their paper, working out a way for human proteins to bind to their own mRNA and package themselves in a protective capsule. That approach differs from the technology used for delivering the mRNA Covid-19 vaccines or for therapies that rely on delivering genetic material into cells, such as gene therapy and CRISPR-Cas9 — all of which utilize lipid nanoparticles or viral vectors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.